Avid Bioservices Selected by Mapp Biopharmaceutical, Inc. for Clinical Development of Novel Human Monoclonal Antiviral Antibody

TUSTIN, Calif., Aug. 26, 2020 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced that Mapp Biopharmaceutical, Inc., has contracted Avid to provide process transfer, scale-up and clinical manufacturing services to support one of its development programs for a novel antiviral drug candidate. Avid and Mapp will immediately commence the initial phase of the project. “We are extremely delighted and honored that Mapp Biopharmaceutical, Inc. contracted Avid Bioservices as their CDMO to support the company’s antiviral program. Today, we are all too familiar with viral outbreaks and, as part of the scientific community, we are proud to leverage our expertise to support the prevention and treatment of challenging viruses,” said Timothy Compton, chief commercial officer of Avid. “This agreement with Mapp Biopharmaceutical provides further evidence of the significant momentum that Avid’s business development team continues to generate toward our dual goals of revenue growth and customer base diversification. We are pleased to add Mapp to our growing list of customers. We are eager to get to work so that we can efficiently move toward To keep reading about Avid Bioservices Selected by Mapp Biopharmaceutical, Inc. for Clinical Development of Novel Human Monoclonal Antiviral Antibody, Click on the link. Seoul, Korea
http://dlvr.it/RfNVmH